Dr. Li recently co-founded three interrelated companies:  Advanced Pharmaceutical Sciences, Inc., a company recently founded by Dr. Li to develop novel technologies and approaches to accurate predict human drug properties; In Vitro ADMET Laboratories, LLC., a contract research service organization to provide in vitro drug metabolism, drug-drug interactions, and toxicity services; and The ADMET Group LLC, a consortium of centers of excellence for drug metabolism and toxicology (Members:  In Vitro ADMET Laboratories, Inc.; (in vitro drug metabolism Contract Research Services); Sitek Inc. (Genotoxicity contract research services); SBChemTox (Analytical and synthetic chemistry); and APSciences, Inc. (novel cell-based assays for drug discovery and development)).  Dr. Li serves as President and CEO of Advanced Pharmaceutical Sciences, Inc. and In Vitro ADMET Laboratories LLC, and Chairman and Chief Scientific Officer of The ADMET Group LLC.  Previously, Dr. Li was President and CEO of Phase 1 Molecular Toxicology, Inc. in Santa Fe, New Mexico, U. S. A. (2002-2003), Chief Scientific Officer of In Vitro Technologies, Inc., Baltimore, Maryland, U. S. A. (1995-2002); Research Professor and Director of the Surgical Research Institute, Department of Surgery, St. Louis University Medical School (1993-1995); Senior Fellow and Director, Liver Biology Department, Monsanto Company (1982 – 1993); Group Leader, Cellular and Genetic Toxicology, Lovelace Inhalation Toxicology Research Institute (1979 – 1982); Assistant Professor and Research Scientist, Cancer Research and Treatment Center and Department of Radiology, University of New Mexico (1976 – 1979).  Dr. Li obtained his B. Sc. (1972, Chemistry) from the University of Wisconsin, Stevens Point, and Ph. D. (1976, Biomedical Sciences) from the University of Tennessee, Oakridge Graduate School of Biomedical Sciences.  His received his doctoral training and performed his dissertation research under Professor Abraham Hsie in the Biology Division of Oak Ridge National Laboratory, Oak Ridge, Tennessee.  Dr. Li is an internationally renowned expert in drug metabolism and toxicology.  He was a pioneer in the application of in vitro systems, especially human-based experimental models such as human hepatocytes, in the evaluation of human drug properties including metabolic fate, drug-drug interactions, and drug toxicity.  He is Editor of Hepatocyte Reports of the journal Chemico-Biological Interactions.  Dr. Li has over 140 publications and edited various books/special journal issues.  He is a frequent invited speaker and  has chaired numerous international symposia and conferences.

Yuichi Sugiyama, Ph.D., born in 1947 , is Professor and Chairman, Department of Biopharmaceutics at the University of Tokyo since 1991. The Department name was recently changed to Molecular Pharmacokinetics.  He has spent all his career at the University of Tokyo. 　He is a coauthor of more than 350 publications in international journals as well as 250 book chapters and review articles (ca.55 written in English), and his main research includes:  (1) Physiologically based pharmacokinetics:  Prediction of drug dispositions from in vitro biochemical data. (2) Kinetic and molecular/biochemical analysis of hepatic, brain and intestinal transport of drugs.  He has received such awards: the 1994 Pharmaceutical Scientist of the Year Award of International Pharmaceutical Federation (FIP); Ebert Prize 1985 of American Pharmaceutical Association; Scientific Achievement Award 1995 from the Academy of Pharmaceutical Science and Technology, Japan (APSTJ); Scientific Achievement Award 2001 from the "Japanese Society for Xenobiotic Metabolism and Disposition";  Takeru-Aya Higuchi Prize 1990; The Troy Daniels Lecturership 2000 from University of California, San Francisco.  He is/was an editorial board member of several  international journals, especially Editor in Japan of  "Pharmaceutical Research" (1992-1996) and “Pharm.Sci.“ (1999-present).  He is serving as the chairman of Board of Pharmaceutical Sciences in FIP (2000-2004) as a successor of Dr. Leslie Benet. He will also chair the “Pharmaceutical Sciences World Conference”, Kyoto, Japan, 2004 (organized by FIP Board of Pharmaceutical Sciences).

Dr. Alan G.E. Wilson is currently Vice President of Drug Metabolism, Pharmacokinetics and Toxicology and Lexcion Genetics. He was formerly Senior Director, Senior Science Fellow in Pre-Clinical Development and also Global Head of Emerging Technologies and In Silico Modeling at Pharmacia Corporation.  He received his Ph.D., in Drug Metabolism from the University of Surrey in the U.K. and was a Science Fellow at the Laboratory of Pharmacology and Pharmacokinetics at National Institute of Environmental Health Sciences in North Carolina. He He has over 22 years of experience in metabolism and pharmacokinetics and mechanistic toxicology in the pharmaceutical, agricultural and chemical industries He was Chairman of the AIHC’s Dosimetry and Risk Assessment Subcommittee, Chairman of the SOCMA Metabolism and Pharmacokinetics Committee, President and founder of the U.S. Whole Body Autoradiography Society, member of ACPA FQPA Committees on Common Mechanisms of Toxicity and Cumulative Risk Assessment, Nominations Committee of ACT, Member of ILSI/HESI SAR and Mechanistic Risk Assessment Committees, ISSX Program Committee and a member of the Editorial Board of Toxicologic Pathology and on the Board of Directors for LHASA, U.K. He is also on the Scientific Advisory Board of Cyprotex Ltd and ICaRuS Japan Ltd. He has over 120 publications, several book chapters, co-editor of several books and is a frequent invited speaker and chairman at numerous symposia and conferences. He is a member of SOT, ACT, ISSX and AACR and board certified by the Academy of Toxicological Sciences

Magang Shou, Ph.D.

Dr. Magang Shou is a Senior Research Fellow in the Department of Drug Metabolism, Merck Research Laboratories.  He received his Ph.D. in Pharmacology at the Uniformed Services University of Health Sciences Medical School, U.S. Department of Defense, Bethesda of Maryland in 1990. Prior to joining Merck in 1996, he was a Senior Staff Fellow at the Laboratory of Molecular Carcinogenesis, National Cancer Institute, NIH, following a short period of post-doctoral training at University of Pennsylvania School of Medicine, Philadelphia.  His research interests include 1) mechanistic and kinetic studies on the cytochrome P450s involved in drug metabolism; 2) studies of unusual enzyme kinetics at the level of CYP3A4; 3) drug metabolism and pharmacokinetics in preclinical drug development; 4) drug-drug interactions associated with cytochrome P450s and other drug metabolizing enzymes (i.e. SULTs, UGTs and FMOs); 5) high throughput screening of NCEs as inhibitors of P450s; 6) cDNA expression of drug metabolizing enzymes in baculovirus system and development of monoclonal antibodies inhibitory to individual P450s and 7) PK-PD correlation.  Dr. Shou has published over 80 peer-reviewed research papers and 2 book chapters, is a member of AACR, AAPS and ISSX, and has been on the Editorial Board of the journal of Drug Metabolism Disposition since 2003.